There are provided a compound of Formula (1) and a labeled biological substance having the compound.

##STR00001##

Z.sup.1 and Z.sup.2 represent a specific 6-membered ring. However, at least one of Z.sup.1 or Z.sup.2 is a benzene ring having a specific substituent at an ortho position with respect to a nitrogen atom to which L.sup.1 or L.sup.2 is bonded, or a specific nitrogen-containing 6-membered ring in which a ring-constituting atom located at the ortho position is a nitrogen atom.

R.sup.1 to R.sup.4, R.sup.11 to R.sup.13, L.sup.1, L.sup.2, and R.sup.21 represents specific groups, and n, α1, α2, and m represent specific numbers.

The compound has at least one structure represented by —(CH.sub.2—CH.sub.2—O).sub.m-R.sup.21 on a heterocyclic ring and has at least one substituent capable of being bonded to a carboxy group or a biological substance at a specific position, and in a case where at least one of Z.sup.1 or Z.sup.2 is the specific nitrogen-containing 6-membered ring, the specific substituents may be bonded to each other to form a ring.

An ICG fluorescence image measured with an excitation light of 740 nm and a fluorescence of 845 nm is shown in FIG. 10, and an ICG fluorescence image measured with an excitation light of 780 nm and a fluorescence of 845 nm is shown in FIG. 11, respectively. As a result, it was observed that the ICG derivative RGD2-PPA-Cy accumulated in the tumor tissue 30 minutes after tail vein administration, regardless of whether the wavelength of the excitation light was 740 nm or 780 nm.

Provided is a coloring composition containing a coloring agent compound represented by Formula 1 and a medium.

##STR00001##

Description of T.sup.1, T.sup.2, R.sup.1, R.sup.2, X.sup.1, and n Formula 1 are omitted.

The present disclosure concerns the design, formulations, preparations and optical properties of compounds of Formulas (I) and (VI):

(charged dye.sup.m+).sub.x.Math.(counterion.sup.n−).sub.y.Math.(counterion receptor).sub.z  (I) and

(charged dye.sup.m−).sub.x.Math.(counterion.sup.n+)y.Math.(counterion receptor).sub.z  (VI).

The charged dye.sup.m+ is a cationic dye, counterion.sup.n− is an anion, and counterion receptor is a binding ligand for the counterion.sup.n−, wherein m, n, x and y are integers greater than or equal to 1, and products of x.Math.n and m.Math.y are identical for formula (I).

The charged dye.sup.m− is a anionic dye, counterion.sup.n+ is a cation, and counterion receptor is a binding ligand for the counterion.sup.n+, wherein m, n, x and y are integers greater than or equal to 1, and products of x.Math.n and m.Math.y are identical for formula (VI).

The present disclosure provides chalcogenopyrylium compounds, composite nanostructures comprising the chalcogenopyrylium compounds, and methods of using the compounds and/or composite nanostructures. For example, composite nanostructures comprising the chalcogenopyrylium compounds are used in imaging applications. The present disclosure provides chalcogenopyrylium compounds having the following structure where each E is, at each occurrence in the compound, independently charged or neutral and is independently selected from S, Se, 0, or Te, wherein at least one E is S or Se; each R1 is, at each occurrence in the compound, independently selected from the group consisting of —H, Ci-s alkyl group, halo group, —CN, aryl group, and heteroaryl group and adjacent R1 groups can combine to form C5ss aryl groups, each R2 is, at each occurrence in the compound.

A fluorescent compound in accordance with exemplary embodiments of the present invention has high stability under a water-soluble condition to be easily stored for a long time and improve pH stability and can be more efficiently used for labeling and dyeing of a target material by introducing the triazine substituted with a hydroxyl group as a linker to improve the fluorescent intensity even at a low concentration as compared with the conventional structure. Further, the fluorescent compound is excellent in optical stability and exhibits stable fluorescence in long-term dyeing, and is excellent in fluorescence intensity while being not accumulated in the body, and thus, can be easily dyed and imaged in vivo even in the use of a small amount as compared with the conventional dyes to be economically used.

A lithographic printing plate precursor is disclosed including on a support a coating comprising (i) a photopolymerisable layer including a polymerisable compound, a first infrared absorbing dye including at least one electron withdrawing substituent and a photoinitiator; and (ii) a top layer provided above the photopolymerisable layer which includes a second infrared absorbing compound which includes a thermocleavable group which transforms into a group which is a stronger electron-donor upon exposure to heat and/or IR radiation, and is capable of forming a print-out image upon exposure to heat and/or IR radiation.

The present invention provides an α-synuclein aggregate binding agent that has high binding selectivity for an α-synuclein aggregate.

The α-synuclein aggregate binding agent contains a compound represented by a formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof:

##STR00001##

in the formula (I), R.sub.1 and R.sub.2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R.sub.3 is hydrogen or halogen; the ring A is a benzene or pyridine ring; the ring B is represented by the following formula (i) or (ii):

##STR00002##

R.sub.4 and R.sub.5 are each independently selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl.

A method for organ imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate or 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate. In one embodiment, the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle.

An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, angsd usage of them.